A Randomized, Phase 3 Study of Rilvegostomig in Combination with Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01)

Clinical Trial Information

Trial Phone: 321-841-7246

Principal Investigator: Jacobo Hincapie-Echeverri, MD

Phase: III

Age Group: ADULTOLDER_ADULT

ClinicalTrials.gov ID: NCT06764875

Objective

To find out if adding the medicine rilvegostomig to trastuzumab deruxtecan and chemotherapy works better and is as safe as the current standard treatment of pembrolizumab with trastuzumab and chemotherapy for people with HER2 positive stomach or GE junction cancer that has spread or cannot be removed.

Share:

Related Clinical Trials

A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) versus Sunitinib in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) after Imatinib Therapy (StrateGIST 3)
A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination with Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)
RETROSPECTIVE REVIEW OF PLAVIX RESISTANCE IN CENTRAL FLORIDA PATIENTS UNDERWENT TRANSCAROTID ARTERY REVASCULARIZATION (TCAR)
Are Premature Infants with Bronchopulmonary Dysplasia Requiring Tracheostomy and Ventilation at Increased Risk of Atypical Craniosynostosis?